Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Satish Jetta
Observed names:
Jetta Satish,
S Jetta,
S. Jetta,
Satish Jeta
Institution:
Suven Life Sciences (India)
Observed institutions:
Suven Life Sciences (India),
Advanced Numerical Research and Analysis Group
OpenAlex ID:
A5110127899
Effect of masupirdine (SUVN‐502) on cognition in patients with moderate Alzheimer's disease: A randomized, double‐blind, phase 2, proof‐of‐concept study
2022
·
Ramakrishna Nirogi
, John Ieni
, et al.
·
Alzheimer s & Dementia Translational Research & Clinical Interventions
·
34
Potential beneficial effects of masupirdine (SUVN‐502) on agitation/aggression and psychosis in patients with moderate Alzheimer's disease: Exploratory post hoc analyses
2022
·
Ramakrishna Nirogi
, Pradeep Jayarajan
, et al.
·
International Journal of Geriatric Psychiatry
·
17
PDF
Simultaneous Determination of Finasteride and Tamsulosin in Combined Dosage Form by Using Rp-hplc Method
2014
·
Mahesh K. Nasare
, Jetta Satish
, et al.
·
Journal of Liquid Chromatography & Related Technologies
·
11
Samelisant (SUVN-G3031), a histamine 3 receptor inverse agonist: Results from the phase 2 double-blind randomized placebo-controlled study for the treatment of excessive daytime sleepiness in adult patients with narcolepsy
2024
·
Ramakrishna Nirogi
, Anil Shinde
, et al.
·
Sleep Medicine
·
10
RP-HPLC method for simultaneous estimation of lamivudine, didanosine andefavirenz in pharmaceutical dosage forms
2013
·
hya
, A. Manikanta Kumar
, et al.
·
Der pharmacia lettre
·
10
Safety, Tolerability, and Pharmacokinetics of SUVN-G3031, a Novel Histamine-3 Receptor Inverse Agonist for the Treatment of Narcolepsy, in Healthy Human Subjects Following Single and Multiple Oral Doses
2020
·
Ramakrishna Nirogi
, Koteshwara Mudigonda
, et al.
·
Clinical Drug Investigation
·
9
Effect of Concurrent Use of Memantine on the Efficacy of Masupirdine (SUVN-502): A Post Hoc Analysis of a Phase 2 Randomized Placebo-Controlled Study
2022
·
Ramakrishna Nirogi
, Vinod Kumar Goyal
, et al.
·
Neurology and Therapy
·
7
PDF
Safety, Tolerability, and Pharmacokinetics of Ropanicant (SUVN-911), a Novel Alpha4 Beta2 Nicotinic Acetylcholine Receptor (α4β2 nAChR) Antagonist, in Healthy Adult and Elderly Subjects
2022
·
Ramakrishna Nirogi
, Vijay Benade
, et al.
·
Clinical Drug Investigation
·
5
First-in-Human Studies to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Novel 5-HT4 Partial Agonist, SUVN-D4010, in Healthy Adult and Elderly Subjects
2021
·
Ramakrishna Nirogi
, Gopinadh Bhyrapuneni
, et al.
·
Clinical Drug Investigation
·
5
Potential benefits of Masupirdine (SUVN-502) on Behavioral and Psychological symptoms in patients with moderate Alzheimer’s Disease (5090)
2020
·
Ramakrishna Nirogi
, Anil Shinde
, et al.
·
Neurology
·
5
Masupirdine (SUVN-502): An Update on the Phase-3 Clinical Development Program Targeting Agitation in Patients with Dementia of Alzheimer’s Type (P1-3.020)
2025
·
Ramakrishna Nirogi
, Jyothsna Ravula
, et al.
·
Neurology
·
3
0609 Samelisant, Histamine 3 Receptor Agonist for the Potential Treatment of Excessive Daytime Sleepiness in Patients with Narcolepsy
2023
·
Ramakrishna Nirogi
, Jyothsna Ravula
, et al.
·
SLEEP
·
3
PDF
Masupirdine (SUVN‐502): Phase‐3 Study for the Potential Treatment of Agitation in Patients with Dementia of the Alzheimer’s Type, an Update
2024
·
Ramakrishna Nirogi
, Renny Abraham
, et al.
·
Alzheimer s & Dementia
·
2
PDF
Masupirdine (SUVN‐502) for the Potential Treatment of Agitation in Patients with Dementia of the Alzheimer’s Type: Preliminary Efficacy and Phase‐3 Study Design
2023
·
Ramakrishna Nirogi
, Renny Abraham
, et al.
·
Alzheimer s & Dementia
·
2
PDF
Effects of Masupirdine (SUVN‐502) on Agitation/Aggression and Psychosis in Patients with Probable Alzheimer’s Disease: A Post Hoc Analysis
2022
·
Ramakrishna Nirogi
, Pradeep Jayarajan
, et al.
·
Alzheimer s & Dementia
·
2
Masupirdine in combination with donepezil and memantine in patients with moderate Alzheimer's disease: Subgroup analyses of memantine regimen, plasma concentrations and duration of treatment
2020
·
Ramakrishna Nirogi
, Vinod Kumar Goyal
, et al.
·
Alzheimer s & Dementia
·
2
PDF
0053 SUVN-G3031: Safety, Tolerability and Pharmacokinetics of a Potent and Selective Histamine H3 Receptor Inverse Agonist - Single and Multiple Ascending Doses in Healthy Subjects
2019
·
Ramakrishna Nirogi
, Anil Shinde
, et al.
·
SLEEP
·
2
Samelisant (SUVN-G3031): Positive Results from Phase-2 Proof-of-concept, Double-blind, Placebo-controlled Study in Patients with Narcolepsy and an Update on Further Clinical Development (S6.004)
2025
·
Ramakrishna Nirogi
, Jyothsna Ravula
, et al.
·
Neurology
·
1
Samelisant (SUVN-G3031) - Topline Results from the Phase-2 Proof-of-Concept Double-blind, Placebo-controlled Study in Patients with Narcolepsy (P10-9.002)
2024
·
Ramakrishna Nirogi
, Pradeep Jayarajan
, et al.
·
Neurology
·
1
Bioequivalence, food effect and comparative pharmacokinetics of SUVN-1105, a novel granule formulation of abiraterone acetate, to Zytiga in healthy male subjects
2023
·
Ramakrishna Nirogi
, Jyothsna Ravula
, et al.
·
Cancer Chemotherapy and Pharmacology
·
1
Development, validation, and application of an ultra-high performance liquid chromatography-tandem mass spectrometry method for the estimation of Ropanicant in human plasma and urine
2022
·
Ramakrishna Nirogi
, Ilayaraja Kalaikadhiban
, et al.
·
Journal of Chromatography Open
·
1
PDF
Masupirdine (SUVN‐502): A promising clinical candidate for the management of agitation in Alzheimer’s dementia
2021
·
Ramakrishna Nirogi
, Pradeep Jayarajan
, et al.
·
Alzheimer s & Dementia
·
1
Masupirdine (SUVN‐502) in combination with donepezil and memantine in moderate Alzheimer's disease: Effect of AD duration since diagnosis and patient’s age on efficacy endpoints
2020
·
Ramakrishna Nirogi
, Anil K Shinde
, et al.
·
Alzheimer s & Dementia
·
1
PDF
Masupirdine (SUVN-502), a 5-HT6 receptor antagonist in combination with Donepezil and Memantine in moderate Alzheimer’s patients (5514)
2020
·
Ramakrishna Nirogi
, Pradeep Jayarajan
, et al.
·
Neurology
·
1
Masupirdine (A Pure 5-HT6 Receptor Antagonist): Clinical Development Program Targeting Agitation in Alzheimer’s Dementia – Phase-3 Study Updates (P3-13.014)
2026
·
Ramakrishna Nirogi
, Satish Jetta
, et al.
·
Neurology
Show more works
View as search
Works count:
44
Citation count:
136
H-index:
7
I10-index:
5
Year
Topic
Type